NASDAQ:TTOO T2 Biosystems (TTOO) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free TTOO Stock Alerts $3.65 +0.65 (+21.67%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$3.09▼$3.7550-Day Range$2.72▼$5.4352-Week Range$2.60▼$70.00Volume255,123 shsAverage Volume275,538 shsMarket Capitalization$20.11 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get T2 Biosystems alerts: Email Address T2 Biosystems MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside17.8% Downside$3.00 Price TargetShort InterestHealthy6.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.81Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.19 out of 5 starsMedical Sector893rd out of 908 stocksSurgical & Medical Instruments Industry94th out of 96 stocks 1.0 Analyst's Opinion Consensus RatingT2 Biosystems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageT2 Biosystems has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.80% of the outstanding shares of T2 Biosystems have been sold short.Short Interest Ratio / Days to CoverT2 Biosystems has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in T2 Biosystems has recently decreased by 5.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldT2 Biosystems does not currently pay a dividend.Dividend GrowthT2 Biosystems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TTOO. Previous Next 0.7 News and Social Media Coverage News SentimentT2 Biosystems has a news sentiment score of -0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for T2 Biosystems this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for TTOO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added T2 Biosystems to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, T2 Biosystems insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of T2 Biosystems is held by insiders.Percentage Held by InstitutionsOnly 23.18% of the stock of T2 Biosystems is held by institutions. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About T2 Biosystems Stock (NASDAQ:TTOO)T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Read More TTOO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTOO Stock News HeadlinesMay 1, 2024 | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) Price Target Cut to $3.00April 24, 2024 | globenewswire.comT2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024May 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 22, 2024 | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head ContrastApril 13, 2024 | investing.comT2 Biosystems converts $15M loan to equity, aims for Nasdaq complianceApril 12, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityApril 11, 2024 | globenewswire.comT2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityMarch 28, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.May 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 28, 2024 | globenewswire.comT2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.March 20, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesMarch 20, 2024 | markets.businessinsider.comT2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick FactsMarch 20, 2024 | globenewswire.comT2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesMarch 19, 2024 | globenewswire.comT2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesMarch 18, 2024 | globenewswire.comT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelMarch 12, 2024 | investorplace.comTTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq ComplianceMarch 12, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementMarch 12, 2024 | globenewswire.comT2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementFebruary 16, 2024 | money.usnews.comT2 Biosystems IncFebruary 16, 2024 | finance.yahoo.comT2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaFebruary 16, 2024 | finance.yahoo.comQ4 2023 T2 Biosystems Inc Earnings CallFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquityFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquitySee More Headlines Receive TTOO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/02/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TTOO CUSIPN/A CIK1492674 Webwww.t2biosystems.com Phone(781) 761-4646Fax781-357-3080Employees113Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside-5.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,080,000.00 Net Margins-696.19% Pretax Margin-696.19% Return on EquityN/A Return on Assets-129.79% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.36 Sales & Book Value Annual Sales$7.19 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value($6.91) per share Price / Book-0.46Miscellaneous Outstanding Shares5,510,000Free Float5,506,000Market Cap$17.41 million OptionableOptionable Beta0.05 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. John J. Sperzel III (Age 61)B.Sc., President, CEO & Chairman Comp: $865.5kMr. John M. Sprague CPA (Age 66)Chief Financial Officer Comp: $581kMr. Michael Terrence Gibbs Esq. (Age 53)Senior VP, General Counsel & Company Secretary Comp: $622.6kMs. Kelley J. Morgan (Age 48)Chief People Officer Mr. Brett A. Giffin (Age 65)Chief Commercial Officer Dr. Roger Smith Ph.D. (Age 59)Senior Vice President of Science Research & Development More ExecutivesKey CompetitorsPAVmedNASDAQ:PAVMMeihua International Medical TechnologiesNASDAQ:MHUASTRATA Skin SciencesNASDAQ:SSKNGlucoTrackNASDAQ:GCTKPolyPidNASDAQ:PYPDView All CompetitorsInsidersGroup L.P. CrSold 59,812 sharesTotal: $1.14 M ($19.00/share)Group L.P. CrSold 2,500 sharesTotal: $62,500.00 ($25.00/share)Group L.P. CrSold 63,382 sharesTotal: $1.90 M ($30.00/share)Group L.P. CrSold 104,014 sharesTotal: $3.85 M ($37.00/share)View All Insider Transactions TTOO Stock Analysis - Frequently Asked Questions Should I buy or sell T2 Biosystems stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares. View TTOO analyst ratings or view top-rated stocks. What is T2 Biosystems' stock price target for 2024? 1 brokers have issued 1-year price objectives for T2 Biosystems' stock. Their TTOO share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 17.8%. View analysts price targets for TTOO or view top-rated stocks among Wall Street analysts. How have TTOO shares performed in 2024? T2 Biosystems' stock was trading at $6.28 at the beginning of 2024. Since then, TTOO stock has decreased by 41.9% and is now trading at $3.65. View the best growth stocks for 2024 here. Are investors shorting T2 Biosystems? T2 Biosystems saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 396,900 shares, an increase of 34.4% from the March 15th total of 295,400 shares. Based on an average daily volume of 255,400 shares, the days-to-cover ratio is presently 1.6 days. Currently, 11.6% of the shares of the company are sold short. View T2 Biosystems' Short Interest. When is T2 Biosystems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our TTOO earnings forecast. How can I listen to T2 Biosystems' earnings call? T2 Biosystems will be holding an earnings conference call on Monday, May 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were T2 Biosystems' earnings last quarter? T2 Biosystems, Inc. (NASDAQ:TTOO) issued its earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($400.00). The medical equipment provider earned $7.43 million during the quarter. During the same quarter in the previous year, the company earned ($400.00) EPS. When did T2 Biosystems' stock split? T2 Biosystems shares reverse split on the morning of Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems issued an update on its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million. What is John McDonough's approval rating as T2 Biosystems' CEO? 36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT). How do I buy shares of T2 Biosystems? Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TTOO) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding T2 Biosystems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
